Julia H.
- Country
- France
- Department
- Hématologie
Research Overview
- TRANSCRIPT: An open label, controlled, randomized multicentric international study evaluating the benefit of autologous stem cell transplantation after complete response in frontline setting patients with T cell-lymphoma
- Evaluation of Blinatumomab, Isatuximab, and Ponatinib in Frontline Therapy for Adults with Acute Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma
- Efficacy of Ziftomenib Combined with Standard of Care Therapy in Patients with Untreated NPM1-Mutated or KMT2A-Rearranged Acute Myeloid Leukemia
Data & Insights
Has run more than one trial at 79 of 170 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating various forms of blood cancers, with particular emphasis on acute myeloid leukemia (AML) and T-cell lymphomas.
- Peripheral T-cell lymphoma management
- AML treatment strategies in adults
- Genomic risk stratification in leukemia
Their clinical focus includes innovative approaches to treating high-risk and intermediate-risk blood cancers.
Stem Cell Therapy
The investigator has developed expertise in stem cell transplantation procedures, including both autologous and allogeneic transplantation approaches.
- Transplantation in lymphoma treatment
- Graft versus host disease prevention
- Stem cell therapy optimization
Their work encompasses transplantation strategies for various hematologic conditions.
Immunotherapy Applications
The investigator focuses on immunotherapeutic approaches in treating blood cancers, particularly in acute lymphoblastic leukemia (ALL).
- Novel immunotherapy agents
- Treatment of Ph-negative and Ph-positive ALL
- Targeted therapy combinations
Their expertise includes integrating immunotherapy into frontline treatment protocols.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.